Goulart BHL, Larkins E, Beaver JA, Singh H, et al. Continuation of Third-Generation Tyrosine Kinase Inhibitors in Second-Line Trials for EGFR-Mutated Non-Small-Cell Lung Cancer: Regulatory Considerations. J Clin Oncol 2023 Jun 8:JCO2300154. doi: 10.1200/JCO.23.00154.
PMID: 37290026